February 15, 2022

The Association for Clinical Oncology (ASCO) congratulates Robert M. Califf, MD, on his confirmation by the United States Senate to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA). 

February 14, 2022

A scoring algorithm that incorporated 290 genetic variants for prostate cancer (PHS290) accurately identified people with high or low lifetime risks of developing metastatic prostate cancer or dying from the disease. Based on the risk scores, people with an African ancestry had the highest risk of developing metastatic prostate cancer and dying of the disease. The study will be presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place February 17-19, 2022, in San Francisco, California.

February 14, 2022

Taking aspirin daily did not improve invasive disease-free survival (iDFS) in breast cancer patients, according to research being presented in the February 15, 2022 ASCO Plenary Series session. 

February 14, 2022

Pancreatic cancer is a leading cause of cancer-related deaths; however, despite decades of research, limited progress has been made to improve survival. There are currently no FDA-approved treatment options for patients with pancreatic cancer that has progressed on first- and second-line chemotherapy. Sotorasib is active and well tolerated in patients with metastatic pancreatic cancer with a KRASG12C mutation, according to research being presented in the February 15, 2022, ASCO Plenary Series session.

February 3, 2022

“This year’s World Cancer Day theme, ‘Close the Care Gap,’ speaks to the heart of what it means to achieve progress against cancer today." 

February 3, 2022

Findings on a scoring algorithm for predicting the risk of developing metastatic or fatal prostate cancer will be highlighted in the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the nearly 600 abstracts that will be presented at the Symposium. 

February 2, 2022

The Association for Clinical Oncology (ASCO) applauds President Biden for his decision to relaunch the Cancer Moonshot with ambitious and worthy goals of reducing the death rate from cancer and improving the experience of patients and families living with cancer.

February 1, 2022

On February 1, 2022, the American Society of Clinical Oncology (ASCO) and the American Cancer Society (ACS) initiated a collaboration to ensure that people can easily find the trusted, expert-approved cancer content they need when turning to either organization for information. As an initial step, the organizations are cross-sharing select cancer prevention, screening, and survivorship resources on their patient and consumer education websites, Cancer.Net and Cancer.org.

January 24, 2022

In patients with advanced gastrointestinal stromal tumors (GIST) that progressed on or were intolerant to imatinib, the efficacy of ripretinib was comparable to sunitinib. These findings from the INTRIGUE trial were presented during the January session of the American Society of Clinical Oncology (ASCO) Plenary Series. 

January 18, 2022

Results from the randomized international phase III TOPAZ-1 trial showed that the checkpoint immunotherapy durvalumab (Imfinzi) plus chemotherapy drugs gemcitabine and cisplatin significantly improved overall survival in patients with advanced biliary tract cancer compared to patients who received a placebo plus the chemotherapy drugs. Biliary tract cancer is classified as a rare disease comprised primarily of bile duct and gallbladder cancers.

January 18, 2022

Results from the randomized international phase III HIMALAYA trial showed that a combination of durvalumab (Imfinzi) plus the experimental drug tremelimumab, both immunotherapies, significantly improved overall survival in patients with advanced, unresectable hepatocellular carcinoma, the most common type of liver cancer, compared to patients who received only sorafenib (Nexavar). 

January 14, 2022

In many areas of the United States, the healthcare system is facing critical workforce shortages. The American Society of Clinical Oncology (ASCO) encourages public health officials and healthcare facilities to follow Centers for Disease Control and Prevention (CDC) guidelines for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-CoV-2. These guidelines allow for different levels of restrictions on staffing based on the level of shortages being experienced. However, in making these decisions, ASCO strongly encourages institutions and public health agencies to recognize the greater risk of infection and adverse outcomes that immune-suppressed individuals, including many patients with cancer, face from SARS-CoV-2 and to make decisions about staffing for the care of those individuals with thoughtful consideration of that greater risk. Unless no alternative exists, COVID-19 positive health workers, even if asymptomatic, should not be assigned to care for patients with cancer

December 23, 2021

Findings on combination therapies with immunotherapy drugs for patients with biliary tract cancer and hepatocellular carcinoma will be highlighted in the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the more than 650 abstracts that will be presented at the Symposium. 

December 17, 2021

Alexandria, VA -- ASCO has elected Lynn M. Schuchter, MD, FASCO, a long-time member and volunteer, to serve as its President beginning in June 2023. Dr. Schuchter will take office as President-Elect immediately after the ASCO Annual Meeting in Chicago in June 2022. Seven new members were also elected to the ASCO Board of Directors and Nominating Committee. This is the first ASCO election to take place under the recently amended Bylaws that were approved by the members last year. These amendments were designed to increase diversity and representation among ASCO elected leaders and have resulted in one of the most diverse groups of incoming Board and Nominating Committee members in ASCO history.

December 16, 2021

Fifty years ago, just a few days before the new year, former President Richard Nixon signed into law the National Cancer Act (NCA), setting a clear national priority to conquer cancer.

Pages